In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs.
BACKGROUND
Infection with Mycobacterium tuberculosis (Mtb) results in different clinical outcomes ranging from asymptomatic containment to rapidly progressing tuberculosis (TB). The mechanisms controlling TB progression in immunologically-competent hosts remain unclear.


RESULTS
To address these mechanisms, we analyzed TB progression in a panel of genetically heterogeneous (A/SnxI/St) F2 mice, originating from TB-highly-susceptible I/St and more resistant A/Sn mice. In F2 mice the rates of TB progression differed. In mice that did not reach terminal stage of infection, TB progression did not correlate with lung Mtb loads. Nor was TB progression correlated with lung expression of factors involved in antibacterial immunity, such as iNOS, IFN-gamma, or IL-12p40. The major characteristics of progressing TB was high lung expression of the inflammation-related factors IL-1beta, IL-6, IL-11 (p<0.0003); CCL3, CCL4, CXCL2 (p<0.002); MMP-8 (p<0.0001). The major predictors of TB progression were high expressions of IL-1beta and IL-11. TNF-alpha had both protective and harmful effects. Factors associated with TB progression were expressed mainly by macrophages (F4-80(+) cells) and granulocytes (Gr-1(hi)/Ly-6G(hi) cells). Macrophages and granulocytes from I/St and A/Sn parental strains exhibited intrinsic differences in the expression of inflammatory factors, suggesting that genetically determined peculiarities of phagocytes transcriptional response could account for the peculiarities of gene expression in the infected lungs. Another characteristic feature of progressing TB was the accumulation in the infected lungs of Gr-1(dim) cells that could contribute to TB progression.


CONCLUSIONS
In a population of immunocompetent hosts, the outcome of TB depends on quantitatively- and genetically-controlled differences in the intensity of inflammatory responses, rather than being a direct consequence of mycobacterial colonization. Local accumulation of Gr-1(dim) cells is a newly identified feature of progressing TB. High expression of IL-1beta and IL-11 are potential risk factors for TB progression and possible targets for TB immunomodulation.
Lyadova
Irina V
IV
Department of Immunology, Central Tuberculosis Research Institute, Russian Academy of Medical Sciences, Moscow, Russian Federation. ivlyadova@mail.ru
Tsiganov
Evgeny N
EN
Kapina
Marina A
MA
Shepelkova
Galena S
GS
Sosunov
Vasily V
VV
Radaeva
Tatiana V
TV
Majorov
Konstantin B
KB
Shmitova
Natalya S
NS
van den Ham
Henk-Jan
HJ
Ganusov
Vitaly V
VV
De Boer
Rob J
RJ
Racine
Rachael
R
Winslow
Gary M
GM
D000818:Animals; D000950:Antigens, Ly / Q000378:metabolism; D015169:Colony Count, Microbial; D003433:Crosses, Genetic; D018450:Disease Progression; D004198:Disease Susceptibility; D005260:Female; D006098:Granulocytes / Q000378:metabolism / Q000473:pathology*; D018836:Inflammation Mediators / Q000378:metabolism; D008168:Lung / Q000382:microbiology / Q000473:pathology*; D008297:Male; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000254:growth & development; D010586:Phagocytes / Q000378:metabolism / Q000473:pathology; D011014:Pneumonia / Q000150:complications / Q000382:microbiology / Q000473:pathology*; D040641:Quantitative Trait Loci / Q000235:genetics; D014376:Tuberculosis / Q000150:complications / Q000235:genetics / Q000382:microbiology / Q000473:pathology*; D015431:Weight Loss
D000950:Antigens, Ly; D018836:Inflammation Mediators; C480309:Ly6G antigen, mouse
J Immunol. 2007 Nov 15;179(10):6919-32
17982083
Blood. 2001 May 1;97(9):2758-63
11313268
J Exp Med. 2008 Feb 18;205(2):305-14
18268037
Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):765-9
1825140
Clin Exp Immunol. 2004 Jan;135(1):19-28
14678260
Infect Immun. 2006 Jun;74(6):3668-72
16714600
Genome Res. 2001 Mar;11(3):325-31
11230157
J Immunol. 2000 Nov 15;165(10):5921-31
11067954
Infect Immun. 2005 Mar;73(3):1744-53
15731075
Annu Rev Immunol. 2005;23:901-44
15771589
Curr Opin Immunol. 2000 Aug;12(4):432-6
10899019
Chest. 2000 Jan;117(1):103-9
10631206
Annu Rev Immunol. 2004;22:599-623
15032590
Infect Genet Evol. 2008 Sep;8(5):541-4
18417424
J Immunol. 2005 Feb 15;174(4):2305-13
15699166
J Dent Res. 2008 Jun;87(6):558-63
18502965
Exp Hematol. 1994 Oct;22(11):1118-23
7523164
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8330-5
12060776
Infect Immun. 2006 Jul;74(7):4295-309
16790804
Infect Immun. 2001 Mar;69(3):1847-55
11179363
Nature. 2005 Apr 7;434(7034):767-72
15815631
Infect Immun. 2003 Jan;71(1):126-31
12496157
Infect Immun. 2003 Oct;71(10):5845-54
14500506
Tuberculosis (Edinb). 2003;83(1-3):4-14
12758183
Novartis Found Symp. 1998;217:3-13; discussion 13-23
9949798
J Reprod Immunol. 2007 Feb;73(1):28-38
16860880
J Infect Dis. 2009 Apr 15;199(8):1222-32
19302011
Exp Biol Med (Maywood). 2004 May;229(5):425-36
15096655
Tuber Lung Dis. 2000;80(1):15-25
10897380
Tuberculosis (Edinb). 2004;84(3-4):144-58
15207484
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8560-5
10890913
J Leukoc Biol. 2003 Aug;74(2):277-86
12885945
J Immunol. 1996 Oct 15;157(8):3627-34
8871663
Am J Respir Crit Care Med. 1996 Feb;153(2):799-804
8564135
J Leukoc Biol. 2007 Jul;82(1):111-23
17438263
Immunology. 2001 May;103(1):1-9
11380686
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6610-5
12740444
Infect Immun. 2003 Feb;71(2):697-707
12540548
Immunol Rev. 2008 Oct;225:284-99
18837789
J Immunol. 2005 Sep 1;175(5):3318-28
16116224
J Immunol. 2007 Jul 15;179(2):1178-89
17617611
J Immunol. 2007 Jan 15;178(2):976-85
17202360
J Infect Dis. 2000 Sep;182(3):902-8
10950787
J Leukoc Biol. 1999 Feb;65(2):217-31
10088605
J Immunol. 1991 Jul 1;147(1):22-8
1711076
Leukemia. 1999 Sep;13(9):1307-15
10482979
J Infect Dis. 1999 Jul;180(1):150-5
10353873
Infect Immun. 1997 Nov;65(11):4843-9
9353074
J Exp Med. 2001 Oct 15;194(8):1123-40
11602641